With the rise in global expenditure on research and development as well as product innovation within the healthcare sector, numerous opportunities are emerging for investors. In this context, healthcare ETFs present significant <a href="https://veye.com.au/editorial/best-healthcare-etfs-asx"> long-term growth</a> potential, provide exposure to a variety of companies in the healthcare industry, and offer cost advantages when compared to actively managed mutual funds.
The iShares Global Healthcare ETF (ASX: IXJ)
grants investors access to leading global healthcare firms by tracking the S&P Global 1200 Healthcare Sector Index. IXJ invests broadly across sectors such as biotechnology, pharmaceuticals, medical equipment, and healthcare service providers. Notable companies in this ETF include Eli Lilly, United Health Group, Novo Nordisk, and Johnson & Johnson. IXJ has a fund size of approximately $1.3 billion and imposes a management fee that ranges from 0.39% to 0.46%.
IXJ has achieved a year-to-date return of about 0.4% and a one-year return of roughly -5.5%. The ETF’s performance over the past three and five years is recorded at 4.97% and 6.96% per annum, respectively. This highlights its appeal for medium to long-term investors.
The VanEck Global Healthcare Leaders ETF (ASX: HLTH)
offers exposure to a selection of 50 fundamentally robust healthcare companies, focusing on developed markets while excluding Australia. The fund targets companies that demonstrate growth at a reasonable price (GARP) across various factors, including growth, value, profitability, and cash flow. It charges an annual management fee of 0.45% and had total net assets of approximately $48.5 million as of August 2025.
HLTH has produced a one-year return of around 1.4% and a three-year annualized return of nearly 4.2%. It also boasts a dividend yield of 0.78%, with payouts occurring once a year.
The BetaShares Global Healthcare Currency Hedged ETF (ASX: DRUG)
tracks the Nasdaq Global ex-Australia Healthcare Hedged AUD Index. It offers Australian Dollar hedged exposure to large global healthcare companies, excluding those based in Australia. The fund employs a passive index-tracking strategy and charges a management fee.